AbClon said partner Henlius expanded clinical programs for HER2 antibody AC101 to nine, adding a Phase 2 colorectal cancer ...

Brelovitug (Mirum Pharmaceuticals) met the primary end point in the phase 3 portion of the phase 2b/3 AZURE-1 study in treatment-naive patients with chronic hepatitis delta virus ...

Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for ...

Vanderbilt Health researchers and colleagues have isolated human monoclonal antibodies from previously infected individuals ...

U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.TX2100 Phase ...

New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patientsReal-world evidence from ...

Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...

The first three participants have been dosed in a nasal spray antibody trial for early-stage ALS, testing whether it can calm ...

Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 µg/kg in the Phase 1 ...

A “life changing” new therapy for an extremely rare medical condition which causes patients to grow a second skeleton has been proven successful in a key clinical trial. Relatives of people living ...

Autoimmune diseases are among the most challenging conditions to diagnose and treat because they can affect almost any organ ...